Inhibition of T-cell signaling pathways by immunophilin drug complexes: are side effects inherent to immunosuppressive properties?
Schreier
M H
MH
Preclinical Research, Sandoz Pharma Ltd, Basel, Switzerland.
Baumann
G
G
Zenke
G
G
D000591:Amino Acid Isomerases / Q000502:physiology*; D000818:Animals; D019703:Calcineurin; D002148:Calmodulin-Binding Proteins / Q000502:physiology; D002352:Carrier Proteins / Q000502:physiology*; D016572:Cyclosporine / Q000494:pharmacology; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008954:Models, Biological; D019696:Peptidylprolyl Isomerase; D010749:Phosphoprotein Phosphatases / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects / Q000276:immunology*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D016559:Tacrolimus / Q000494:pharmacology; D022021:Tacrolimus Binding Proteins; D014714:Vertebrates
D002148:Calmodulin-Binding Proteins; D002352:Carrier Proteins; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D019703:Calcineurin; D010749:Phosphoprotein Phosphatases; D000591:Amino Acid Isomerases; D022021:Tacrolimus Binding Proteins; D019696:Peptidylprolyl Isomerase; D016559:Tacrolimus